Back to Authors

Berdeja, J. G.

A5082897883 | I4210100810

Mayo Clinic

Sarah Cannon

Citations 4

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 851-852

10.1097/01.hs9.0000846712.74284.0f

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 861-862

10.1097/01.hs9.0000846752.50612.48

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 18-18

10.1097/01.hs9.0000829624.40467.0d

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 8-8

10.1097/01.hs9.0000829560.21894.ee